英语翻译MGMT promoter methylation in malignant gliomasThe O(6)-m

英语翻译
MGMT promoter methylation in malignant gliomas
The O(6)-methylguanine-DNA methyltransferase (MGMT) gene is located at chromosome 10q26 and codes for a DNA repair enzyme that--if active--can counteract the effects of alkylating chemotherapy.Malignant gliomas often have the MGMT gene inactivated due to aberrant methylation of its promoter region.The assessment of the MGMT promoter methylation status has become of clinical relevance as a molecular marker associated with response to alkylating chemotherapy and prolonged survival of glioblastoma patients.MGMT promoter methylation testing is also on the merge of being used as a marker for patient selection within clinical trials,e.g.,the current CENTRIC trial that is specifically focusing on patients with MGMT promoter-methylated glioblastomas.In anaplastic gliomas,MGMT promoter methylation is a favorable prognostic marker independent of the type of therapy,i.e.,radio- or chemotherapy.This occurrence might be associated with the high incidence of other prognostically favorable molecular markers in these tumors,such as IDH1 mutation,1p/19q deletion or yet to be identified novel aberrations.A variety of different methods are being used to assess MGMT promoter methylation in clinical samples,which may give rise to inter-laboratory variations in test results.Immunohistochemical determination of MGMT protein expression has not proven reliable for diagnostic purposes.This brief review article aims to summarize the main aspects of MGMT promoter methylation testing in contemporary neuro-oncology,in particular its value as a clinically useful molecular marker,putting it into the context of other molecular markers of clinical use in gliomas of adult patients.

在恶性神经胶质瘤基因启动子甲基化的管理
(6)-methylguanine-DNA O的methyltransferase(管理)基因位于染色体10q26和代码,为一种DNA修复酶——如果活跃,可中和效果的烷基化化疗.恶性胶质瘤通常有管理基因的异常甲基化注射的方式接种灭活的,由于它的子区域.评估工厂人力资源管理已成为基因启动子甲基化状态的临床意义是一种分子标记物烷基化反应相关的化疗和延长了生存期的恶性胶质瘤患者.管理基因启动子甲基化测试也在合并,被用来作为标记为患者选择在临床试验中,例如,目前具体以人为中心的实验是glioblastomas管理promoter-methylated患者.在未分化胶质瘤,管理启动子甲基化是一个良好的预后标志物独立的类型的治疗,也就是说,收音机-或化疗.这个出现可能导致的高发病率,其他prognostically有利的分子标记技术在这些肿瘤,如IDH1突变所示,主机/ 19q删除或还没有被确认小说畸变.有各种不同的方法被用来评估管理基因启动子甲基化在临床样本,这可能会导致实验室内部的变化的测试结果.免疫组化测定管理蛋白表达还没有证明可靠的诊断的目的.这篇文章旨在总结简要回顾工厂人力资源管理的重点测试在当代神经肿瘤学学会举办基因启动子甲基化,尤其是其价值作为临床使用分子标记、投入的语境中,其他分子标记在脑胶质瘤的临床使用的成年患者.